ZyVersa Therapeutics shares are trading higher after HC Wainwright initiated coverage on the stock with Buy rating and price target of $2.5.
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright has initiated coverage on ZyVersa Therapeutics with a Buy rating and a price target of $2.5. This has led to an increase in the trading of ZyVersa shares.
September 08, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ZyVersa Therapeutics' stock is trading higher after HC Wainwright initiated coverage with a Buy rating and a price target of $2.5.
The initiation of coverage by HC Wainwright with a Buy rating and a price target of $2.5 is a positive signal for investors, which has led to an increase in the trading of ZyVersa shares. This suggests a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100